Keymed Biosciences Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bo Chen

Chief Executive Officer (CEO)

CN¥4.8m

Compensación total

Porcentaje del salario del CEO	95.9%
Permanencia del CEO	3.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bo Chen en comparación con los beneficios de Keymed Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥743m
Mar 31 2024	n/a	n/a	-CN¥551m
Dec 31 2023	CN¥5m	CN¥5m	-CN¥359m
Sep 30 2023	n/a	n/a	-CN¥313m
Jun 30 2023	n/a	n/a	-CN¥267m
Mar 31 2023	n/a	n/a	-CN¥287m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥308m
Sep 30 2022	n/a	n/a	-CN¥281m
Jun 30 2022	n/a	n/a	-CN¥253m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥4m	CN¥4m	-CN¥4b
Sep 30 2021	n/a	n/a	-CN¥4b
Jun 30 2021	n/a	n/a	-CN¥4b
Mar 31 2021	n/a	n/a	-CN¥3b
Dec 31 2020	CN¥231k	CN¥227k	-CN¥819m
Dec 31 2019	CN¥188k	CN¥183k	-CN¥168m

Compensación vs. Mercado: La compensación total de Bo($USD660.83K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD487.48K).

Compensación vs. Ingresos: La compensación de Bo ha aumentado mientras la empresa no es rentable.

CEO

Bo Chen (49 yo)

3.6yrs

Permanencia

CN¥4,788,000

Compensación

Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bo Chen	Executive Chairman & CEO	3.6yrs	CN¥4.79m	sin datos
Gang Xu	Senior VP & Executive Director	3.6yrs	CN¥1.61m	sin datos
Changyun Wang	Senior VP & Executive Director	6.5yrs	CN¥2.81m	sin datos
Qi Chen	Senior VP & Non Executive Director	6.7yrs	CN¥178.00k	sin datos
Yanrong Zhang	CFO, VP & Joint Company Secretary	4.2yrs	sin datos	sin datos
Qian Jia	Senior Vice President	6.7yrs	sin datos	sin datos
Pak Yu Tam	Joint Company Secretary	2.7yrs	sin datos	sin datos

4.2yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2162 se considera experimentado (4.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bo Chen	Executive Chairman & CEO	6.6yrs	CN¥4.79m	sin datos
Gang Xu	Senior VP & Executive Director	6.4yrs	CN¥1.61m	sin datos
Changyun Wang	Senior VP & Executive Director	3.7yrs	CN¥2.81m	sin datos
Qi Chen	Senior VP & Non Executive Director	6.4yrs	CN¥178.00k	sin datos
Cheuk Kin Law	Independent Non Executive Director	3.6yrs	CN¥572.00k	sin datos
Yang Ke	Independent Non Executive Director	3.6yrs	CN¥476.00k	sin datos
Xiao-Fan Wang	Independent Non-Executive Director	3.6yrs	CN¥476.00k	sin datos
Yilun Liu	Non Executive Director	3.7yrs	sin datos	sin datos
Min Chuan Wang	Non Executive Director	3.7yrs	sin datos	sin datos

3.7yrs

Permanencia media

49yo

Promedio de edad

Junta con experiencia: La junta directiva de 2162 se considera experimentada (3.7 años de antigüedad promedio).

Keymed Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Keymed Biosciences Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Keymed Biosciences Inc. Receives Marketing Approval from National Medical Products Administration for the Treatment of Moderate-To-Severe Atopic Dermatis in Adults

First half 2024 earnings released: CN¥1.29 loss per share (vs CN¥0.18 profit in 1H 2023)

Keymed Biosciences Inc. to Report First Half, 2024 Results on Aug 27, 2024

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis

Full year 2023 earnings released: CN¥1.38 loss per share (vs CN¥1.18 loss in FY 2022)

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: CN¥1.37 loss per share (vs CN¥1.18 loss in FY 2022)

Keymed Biosciences Inc. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection

Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901

Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023

Now 21% undervalued

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Now 21% undervalued

Now 22% undervalued

First half 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.021 in 1H 2022)

Keymed Biosciences Inc. to Report First Half, 2023 Results on Aug 24, 2023

Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313

Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults

Keymed Biosciences Inc. Announces Latest Results from the Phase Ia Clinical Study of CMG901 at the 2023 ASCO GI CANCERS SYMPOSIUM

Less than half of directors are independent

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the China National Medical Products Administration Granted CMG901 the Breakthrough Therapy Designation for the Treatment of Advanced Gastric and Gastroesophageal Junction

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the National Medical Products Administration Has Granted CMG90

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

Keymed Biosciences Inc. to Report First Half, 2022 Results on Aug 29, 2022

Keymed Biosciences Inc. Receives Grants from Center for Drug Evaluation of the National Medical Products Administration for CM310

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

Less than half of directors are independent

U.S. Food and Drug Administration Grants CMG901 Fast Track Designation as Monotherapy for the Treatment of Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer

Keymed Biosciences Inc. Announces Phase II Clinical Study of its Self-Developed Class1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection

Keymed Biosciences Inc. Announces Executive Changes

High number of new and inexperienced directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad